Navigation Links
Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
Date:7/7/2008

V."

Steve Worland, Ph.D., Anadys' President and CEO, commented, "The decision to take ANA773 into HCV, which will be our third clinical development program to commence dosing this year, reflects an expansion of Anadys' development efforts in HCV. As an approach to treat hepatitis C, the TLR7 mechanism is independent from, and potentially complementary to, ANA598, Anadys' non-nucleoside HCV polymerase inhibitor currently in Phase I clinical development." Commenting on the expected impact this expansion will have on the Company's cash outlook for 2008, Dr. Worland added, "Because the ANA773 hepatitis C program is highly leveraged off our oncology program, we expect to carry forward all three clinical development programs this year within our previous 2008 cash utilization projection of $29 to $31 million."

ANA773 Phase I Clinical Trial in HCV

The Phase I clinical trial of ANA773 in HCV will be conducted under a two-part protocol. Part A of the study will include both single and multiple doses of ANA773 in healthy volunteers. Successive cohorts of volunteers will receive ascending dose levels of ANA773. The primary objectives of Part A of the study are to assess safety and tolerability. In Part B of the study, HCV patients will receive ANA773 every other day for 28 days. The primary objectives of Part B are to assess safety, tolerability and viral load decline. The starting dose level in HCV patients will be selected based on safety, tolerability and immune responses seen in healthy volunteers in Part A. It is expected that this study design will allow initial dosing in HCV patients at a dose that will have demonstrated a desired magnitude of immune stimulation in the healthy subjects, and that dosing in patients will initiate prior to completion of dose escalation in Part A of the study. Approximately 40 healthy volunteers and 24 patients are anticipated to be enrolled in this study. Dosing is expected to begin in healthy volunteers within the nex
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
2. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
3. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
6. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
7. Isis Pharmaceuticals Conference Call Notice
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
9. XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
10. MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
11. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... 2015  PARI Respiratory Equipment has won a 2015 American ... approved by the FDA on December 2, is the first ... PLUS ® Nebulizer for patients with cystic fibrosis. ... put into this unique product offering of nebulized drug and ... to use, we also wanted to convey that the components ...
(Date:6/3/2015)... LONDON , June 3, 2015 ... clinical gaps in the market, says  GBI Research ... provider GBI Research - Acute Myeloid Leukemia Therapeutics Market ... AML therapeutics market to increase moderately from $632.6 million in ... Growth Rate (CAGR) of 4.8%. Several drugs to ...
(Date:6/3/2015)... 3, 2015  Varian Medical Systems (NYSE: VAR ), world ... cancer, is expanding in the Middle East ... Saudi Arabia . Varian Medical Systems Arabia, the ... was officially launched today at a ceremony attended by local ... "This move represents the next step in our commitment ...
Breaking Medicine Technology:Kitabis Pak Wins American Package Design Award 2Novel Acute Myeloid Leukemia Therapies to Offer Clinical Benefit in Small Patient Cohorts 2Novel Acute Myeloid Leukemia Therapies to Offer Clinical Benefit in Small Patient Cohorts 3Varian Establishes Local Entity in Saudi Arabia to Support Expansion in Middle East 2
(Date:6/3/2015)... Baltimore, MD (PRWEB) June 03, 2015 On ... be a $13 billion industry by 2020 ( click here ... and Markets), computer scientists believe Baltimore has the ... fast-growing industry in which genetic code and other biological data ... and cure disease. “Baltimore contains all the elements of ...
(Date:6/3/2015)... Alberto Grignolo, PhD, will be honored ... Meeting. DIA’s Global Inspire Award program recognizes the organization’s ... commitment to service on a global scale. ... annually recognizes one DIA member for meritorious service through ... DIA to foster innovation to improve health and well-being ...
(Date:6/3/2015)... CT (PRWEB) June 03, 2015 Z-Medica®, ... announces today since June has been designated as National ... commends the Tucson, AZ. Police Department for its commitment ... its personnel utilized their Individual First Aid Kits (IFAK) ... civilians involved in shootings, stabbings or traffic accidents. Each ...
(Date:6/3/2015)... 03, 2015 Sitting at a computer ... in the back, neck, shoulders and/or wrists. This can ... In addition, recent research links sitting for long periods ... diseases. Fortunately, three inventors from Oakville, Ontario, are offering ... desk. , They have developed a prototype for a ...
(Date:6/3/2015)... Implant design can have a profound ... unites bone to an implant surface. The unique triangular-shape ... to encourage bone regeneration, resulting in the gain of ... soft tissues for more esthetic restorations. , “It’s all ... MIS Implants. The triangular neck of the V3 provides ...
Breaking Medicine News(10 mins):Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 2Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 3Health News:Longtime DIA Champion and PAREXEL Executive Honored with Global Inspire Award at DIA’s Annual Meeting 2Health News:Longtime DIA Champion and PAREXEL Executive Honored with Global Inspire Award at DIA’s Annual Meeting 3Health News:Z-Medica Commends Tucson Police Department for Trauma Kit Utilization 2Health News:Adjustable Height Tabletop Unit Invented by Three InventHelp® Clients (TOR-9278) 2Health News:MIS Implants Launches Radically New V3 Dental Implant For Immediate Biological Benefits 2
... Glucotrace (Fluorodeoxyglucose) for Use in Earlier, ... FLEURUS, Belgium, May 28 /PRNewswire-FirstCall/ - MDS Nordion, ... radiopharmaceuticals used in molecular medicine, today announced the ... the production of Glucotrace (Fluorodeoxyglucose), a radiopharmaceutical used ...
... results beyond soothing of infants, , , WEDNESDAY, May 27 ... and encourage feeding in premature infants, University of Alberta ... neonatal units across North America, but how beneficial it ... Dr. Manoj Kumar, an assistant clinical professor in the ...
... The Lance Armstrong Foundation (LAF) and Penn ... develop and disseminate the LIVESTRONG Care Plan Powered ... cancer survivors, their families and physicians the ability ... up-to-date treatment information based on Institute of Medicine ...
... HARRISBURG, Pa., May 27 Secretary of Public Welfare ... Smart Pharmacy initiative, saying the plan would save taxpayers ... the pharmacy initiative for providers. "The savings from the ... Richman. "This is not a drill. Pennsylvania is facing ...
... ROCHESTER, Minn. -- Researchers have discovered a novel molecular path ... that mainly affects women and slowly destroys their livers. Primary ... because it is a first step toward developing a targeted ... 11, 2009, issue of the New England Journal ...
... co-sponsored by W.K. Kellogg Foundation WASHINGTON, May 27 ... Friedman School of Nutrition Science & Policy will present ... on the most pressing nutrition and health policy issues ... join academic, corporate and government colleagues for an in-depth ...
Cached Medicine News:Health News:MDS Nordion Opens New Radiopharmaceutical Production Facility in Belgium 2Health News:Music May Temper Pain in Preemies 2Health News:Music May Temper Pain in Preemies 3Health News:LIVESTRONG and Penn Medicine announce partnership to bring online care plan tool to cancer survivors 2Health News:Secretary of Public Welfare Corrects the Record on 'Smart Pharmacy' Initiative 2Health News:Mayo researchers help discover genetic cause for primary biliary cirrhosis 2Health News:Mayo researchers help discover genetic cause for primary biliary cirrhosis 3Health News:Tufts University Friedman School of Nutrition Presents National Forum: 'Children's Health: The Future of Food & Nutrition Policy' 2
Fortitude as a unique complement to the spinal concepts family of products....
... implant made of radiolucent carbon fiber ... has a modulus of elasticity approximating ... is an implant that meets the ... while optimizing the fusion environment through ...
... Spinal Implant system. Material that has a ... bone. The result is an implant that ... support, while optimizing the fusion environment through ... anatomic design with 5 and 10 degrees ...
Caspar cervical retractor (lamina spreader), counter-retractor complete with 5 blades and forceps. Height: max. 165 mm, Maximal spread: 85 mm...
Medicine Products: